RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental myeloma drug trial halted early
Disease control TerminatedThis early-stage study tested a drug called AMG 420 in 23 people with multiple myeloma that had returned or stopped responding to prior treatments. The goal was to find a safe dose and check for side effects. The study was stopped early, so results are limited.
Matched conditions: RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated May 17, 2026 11:39 UTC
-
Promising myeloma combo study halted after just 2 patients
Disease control TerminatedThis study tested a new oral drug (narazaciclib) plus a steroid (dexamethasone) in people with multiple myeloma that returned after other treatments. The goal was to find a safe dose and see if it could control the cancer. Only 2 people enrolled before the study was stopped early…
Matched conditions: RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Adriana Rossi • Aim: Disease control
Last updated May 13, 2026 16:00 UTC